Tags: Drug.
Rovelizumab also known as LeukArrest and Hu23F2G is a humanized monoclonal antibody which was an experimental immunosuppressive drug. Rovelizumab was developed by Icos to treat patients suffering from haemorrhagic shock. The drug is a monoclonal antibody that suppresses white blood cells which become overly active during shock. During testing the number of patients given the drug was low because rovelizumab had to be delivered within four hours of the injury and consent was required.